Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 25 entries
View as:

A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT02309359 Org: User:
Start: 01/31/15 End: 08/31/16 Due: 08/31/17

Study to Assess Safety and Efficacy of Anti-Interleukin 6-receptor (IL6R) Nanobody in Rheumatoid Arthritis (RA) Patients

Phase: N/A Priority: Normal
NCT ID: NCT01284569 Org: User:
Start: 03/31/11 End: 09/30/12 Due: 09/30/13

Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT01063803 Org: User:
Start: 02/28/10 End: 02/29/12 Due: 02/28/13

An Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of ALX-0061 in Subjects With Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT02518620 Org: User:
Start: 07/31/15 End: 08/31/18 Due: 08/31/19

Dose Ranging Study of ALX-0171 in Infants Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection

Phase: N/A Priority: Normal
NCT ID: NCT02979431 Org: User:
Start: 01/11/17 End: 05/25/18 Due: 05/25/19

Study Of Single Dose Of ATN-103 Administered To Healthy Japanese Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT00916110 Org: User:
Start: 11/30/08 End: 11/30/09 Due: 11/30/10

ALX-0171 Phase I Pharmacokinetic Study in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01875926 Org: User:
Start: 05/31/13 End: 10/31/13 Due: 10/31/14

Efficacy and Safety of ALX-0171 in Adult Hematopoietic Stem Cell Transplant (HSCT) Recipients Who Present With Respiratory Syncytial Virus (RSV) Infection

Phase: N/A Priority: Normal
NCT ID: NCT03468829 Org: User:
Start: 02/28/19 End: 05/31/20 Due: 05/31/21

ALX-0171 Phase I Study, Evaluating Single Ascending Dose and Multiple Dose in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01483911 Org: User:
Start: 11/30/11 End: 05/31/12 Due: 05/31/13

Study Evaluating Multiple Doses Of ATN-103 In Subjects With Active Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT00959036 Org: User:
Start: 09/30/09 End: 01/31/11 Due: 01/31/12

Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) Patients

Phase: N/A Priority: Normal
NCT ID: NCT01020383 Org: User:
Start: 09/30/09 End: 03/31/12 Due: 03/31/13

Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura

Phase: N/A Priority: Normal
NCT ID: NCT02553317 Org: User:
Start: 11/30/15 End: 08/31/17 Due: 08/31/18

Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

Phase: N/A Priority: Normal
NCT ID: NCT01151423 Org: User:
Start: 01/31/11 End: 03/31/14 Due: 03/31/15

ALX-0171 Safety Study in Adults With Hyperresponsive Airways

Phase: N/A Priority: Normal
NCT ID: NCT01909843 Org: User:
Start: 07/31/13 End: 12/31/13 Due: 12/31/14

A Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With RSV Lower Respiratory Tract Infection to Evaluate the Safety, Tolerability, and Clinical Activity of ALX-0171

Phase: N/A Priority: Normal
NCT ID: NCT02309320 Org: User:
Start: 12/31/14 End: 02/29/16 Due: 02/28/17

Bioequivalence of Liquid and Reconstituted Lyophilized Subcutaneous Formulations of Caplacizumab.

Phase: N/A Priority: Normal
NCT ID: NCT02189733 Org: User:
Start: 07/31/14 End: - Due: -

First in Man Study of ALX-0651, a Nanobody Inhibiting CXCR4

Phase: N/A Priority: Normal
NCT ID: NCT01374503 Org: User:
Start: 06/30/11 End: 01/31/12 Due: 01/31/13

Caplacizumab Single and Multiple Dose Study in Healthy Japanese and White Subjects.

Phase: N/A Priority: Normal
NCT ID: NCT03172208 Org: User:
Start: 06/05/17 End: 10/19/17 Due: 10/19/18

Study Evaluating Multiple Ascending Doses Of ATN-103 In Japanese Subjects With Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT01007175 Org: User:
Start: 11/30/09 End: 09/30/10 Due: 09/30/11

Evaluation of ALX-0171 in Japanese Children Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection

Phase: N/A Priority: Normal
NCT ID: NCT03418571 Org: User:
Start: 03/01/18 End: 10/24/18 Due: 10/24/19

A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT02287922 Org: User:
Start: 03/31/15 End: 07/31/16 Due: 07/31/17

A Single Dose Study Of The Safety And Investigational Product Level Measurement In Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01284036 Org: User:
Start: 10/31/10 End: 11/30/11 Due: 11/30/12

A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT02437890 Org: User:
Start: 07/31/15 End: 01/31/18 Due: 01/31/19

ALX-0061 Phase I Bioavailability Study in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02101073 Org: User:
Start: 03/31/14 End: 07/31/14 Due: 07/31/15

Study Comparing The Tolerability Of Three Excipient Formulations Administered Subcutaneously To Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01401764 Org: User:
Start: 05/31/11 End: 06/30/11 Due: 06/30/12